Anzeige
Mehr »
Sonntag, 04.05.2025 - Börsentäglich über 12.000 News
Rebranding vollzogen - Copper Giant startet durch mit Monster-Bohrungen in Mocoa!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853260 | ISIN: US4781601046 | Ticker-Symbol: JNJ
Tradegate
02.05.25 | 21:57
138,12 Euro
+0,03 % +0,04
1-Jahres-Chart
JOHNSON & JOHNSON Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON 5-Tage-Chart
RealtimeGeldBriefZeit
137,50138,6219:05
137,88138,2802.05.

Aktuelle News zur JOHNSON & JOHNSON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
JOHNSON & JOHNSON Aktie jetzt für 0€ handeln
FrJohnson & Johnson's Imaavy granted FDA approval for rare autoimmune disease gMG5
FrHistoSonics reportedly eyes sale at $2.5B valuation with Medtronic, GE HealthCare, J&J interest4
FrJ&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports3
DoFDA Nod for J&J Autoimmune Drug is First of Potentially Many for the Projected Blockbuster Product3
DoReese Marketos LLP: Reese Marketos and Berger Montague Secure Historic $1.64 Billion False Claims Act Judgment Against Johnson & Johnson Subsidiary397DALLAS, TEXAS / ACCESS Newswire / May 1, 2025 / In a landmark decision, law firms Reese Marketos and Berger Montague have secured a $1.64 billion judgment against Janssen Products, LP, a subsidiary...
► Artikel lesen
DoJ&J's IMAAVY Approved by FDA for Treatment of Generalized Myasthenia Gravis5
DoGoldman Sachs updates conviction lists: Adds Johnson & Johnson and Axis Bank12
DoFDA approves J&J's Imaavy for generalised myasthenia gravis5
DoGoldman adds Houlihan Lokey, Johnson & Johnson to Conviction List6
DoJ&J's 'Swiss army knife' drug gets first FDA approval2
MiJohnson & Johnson (JNJ): Jim Cramer Says "They Love the Weak Dollar" - Is This Quiet Giant Back in Favor?2
MiJOHNSON & JOHNSON - 8-K, Current Report3
MiJ&J secures FDA OK for immune drug touted as future blockbuster4
MiJ&J joins Argenx, UCB in the myasthenia gravis arena with FDA approval for FcRn blocker Imaavy14
MiJohnson & Johnson Announces FDA Approval Of IMAAVY278NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced the FDA has approved IMAAVY, a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis. The approval...
► Artikel lesen
MiJohnson & Johnson receives FDA approval for IMAAVY (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)102First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and...
► Artikel lesen
DiThree Cheap Stocks: Skechers, J&J, and P&G15
DiNvidia, JNJ, Toyota chiefs among White House guests for investment event- report16
DiNvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report22
DiTrump to tout US investments from Nvidia, J&J, Hyundai, Toyota43
Seite:  Weiter >>
816 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
8,1,16